On the basis of a previous study and our findings, we propose that targeting the TXNIP-NLRP3 inflammasome pathway may represent a therapeutic approach to attenuate liver injury during HFD-induced NAFLD. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.